PHLPP1

PH domain leucine-rich repeat-containing protein phosphatase 1 · O60346 · PHLPP1 on Sugi Atlas →

1,131 patent compounds predicted against PHLPP1, 958 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL15441208	1.00	3/20
SCHEMBL15441338	1.00	3/20
SCHEMBL15441594	1.00	3/20
SCHEMBL15441595	1.00	3/20
Gamma-Tocopherol (SCHEMBL39640)	0.91	3/20
Gamma-Tocopherol (SCHEMBL120346)	0.91	3/20
Gamma-Tocopherol (SCHEMBL8408124)	0.91	3/20
Gamma-Tocopherol (SCHEMBL14580952)	0.91	3/20
Gamma-Tocopherol (SCHEMBL14695405)	0.91	3/20
SCHEMBL15441242	0.91	3/20
Gamma-Tocopherol (SCHEMBL16430717)	0.91	3/20
Gamma-Tocopherol (SCHEMBL17874900)	0.91	3/20
SCHEMBL9945494	0.89	3/20
Gamma-Tocopherol (SCHEMBL8652038)	0.82	3/20
Gamma-Tocopherol (SCHEMBL8894990)	0.82	3/20
Gamma-Tocopherol (SCHEMBL1187698)	0.80	3/20
Gamma-Tocopherol (SCHEMBL8893560)	0.80	3/20
SCHEMBL15441414	0.78	3/20
Bromide (SCHEMBL8600259)	0.76	3/20
SCHEMBL5773613	0.73	3/20

Clinical trials — most relevant to PHLPP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2	PHASE1/PHASE2	COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA	nan	RECRUITING
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly	nan	UNKNOWN
Proteomics of Primary Hyperoxaluria Type 1	nan	COMPLETED
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease.	nan	UNKNOWN
Vitreous Proteomics of Patients Suffering From Pseudoexfoliation Syndrome	nan	ACTIVE_NOT_RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients	nan	UNKNOWN
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Study of Proteins in Head and Neck Cancer Cells	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Autophagy Bladder Cancer	nan	UNKNOWN
QoL and Cognitive Function in Patients With Hypoparathyroidism	nan	COMPLETED
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PHLPP1 binder may also engage these)

Protein	Name	Similarity
Q8CHE4	—	1.000	Q8CHE4 →
Q9WTR8	—	0.997	Q9WTR8 →
Q6NS60	—	0.981	Q6NS60 →
Q8TF61	—	0.978	Q8TF61 →
P53349	—	0.975	P53349 →
Q9WU40	—	0.975	Q9WU40 →
Q62925	—	0.974	Q62925 →
Q9BYB0	—	0.974	Q9BYB0 →
Q68FM6	—	0.973	Q68FM6 →
A0FI79	—	0.972	A0FI79 →
Q8R554	—	0.972	Q8R554 →
Q8VCC6	—	0.971	Q8VCC6 →
Q9UQF2	—	0.971	Q9UQF2 →
Q9WVI9	—	0.971	Q9WVI9 →
Q9Y6J9	—	0.970	Q9Y6J9 →
Q8N2R8	—	0.970	Q8N2R8 →
Q9QZN1	—	0.969	Q9QZN1 →
P0C7U0	—	0.969	P0C7U0 →
Q6PAJ3	—	0.969	Q6PAJ3 →
Q75VX8	—	0.969	Q75VX8 →
Q6PDJ6	—	0.969	Q6PDJ6 →
Q96C00	—	0.969	Q96C00 →
Q8C8T7	—	0.968	Q8C8T7 →
Q61127	—	0.968	Q61127 →
Q8WXD9	—	0.968	Q8WXD9 →
MAP3K1	Mitogen-activated protein kinase kinase kinase 1	0.968	landscape →
Q5R3F8	—	0.968	Q5R3F8 →
D3YYI7	—	0.968	D3YYI7 →
A4D2P6	—	0.967	A4D2P6 →
Q8K0Z9	—	0.967	Q8K0Z9 →